Last updated: May 29, 2026
Fluticasone Propionate and Salmeterol Xinafoate: Key Suppliers, Contract Manufacturing Footprint, and Upstream Input Sources
Suppliers for fluticasone propionate and salmeterol xinafoate span three layers: active pharmaceutical ingredients (APIs), key starting materials and intermediates, and finished-dose inhaler manufacturing (contract manufacturing organizations, packaging, and device supply). In the US, the supply chain is dominated by vertically integrated originator programs plus a long tail of API and inhalation-device CMOs and packagers.
Because “suppliers” in practice means different things depending on whether you are sourcing API, intermediates, or finished product, the sections below map the supply ecosystem at the level that supports procurement, sourcing, and IP due diligence.
Which companies supply fluticasone propionate API for inhalation products?
Fluticasone propionate is a synthetic corticosteroid API manufactured through multi-step chemical synthesis and typically sold globally as GMP API or in some cases as drug substance to inhalation product manufacturers. The supplier set tends to be stable for long-cycle inhalation programs because qualification and change-management are slow.
Common fluticasone propionate API supplier archetypes
- Large-scale fine-chemical API manufacturers with regulatory history in US/EU
- Specialty inhalation-focused API makers that can support complex impurity control
- API-to-drug-substance contractors supplying drug substance rather than commercial API barrels
What procurement teams actually need
- DMF coverage or ASMF readiness for US
- impurity profiles and specification management for corticosteroid class compounds
- ability to support inhalation-grade particle and polymorph expectations for downstream formulation
Which companies supply salmeterol xinafoate API for inhalation products?
Salmeterol xinafoate is a synthetic long-acting beta2-agonist (LABA) salt API. Supply is concentrated in companies that can control salt form, impurity pathways, and residual solvents for inhalation-grade use.
Salmeterol xinafoate: supplier requirements that filter vendors
- validated salt form consistency (xinafoate)
- tight control of genotoxic impurities (class-driven impurity targets)
- consistent particle size distribution where downstream spray-drying or blending is sensitive
How this affects supplier selection
Qualification tends to lock in a small number of approved suppliers because any change can ripple into formulation performance, metered dose consistency, and device-drug compatibility.
Who manufactures combination fluticasone/salmeterol inhalers under contract?
For combination products (fluticasone propionate + salmeterol xinafoate), contract manufacturing is commonly used for:
- drug product filling and finishing (DP)
- packaging and labeling
- inhaler device assembly (for some platforms)
- inhaler performance qualification batch production
Key CMO roles in the fluticasone/salmeterol supply chain
- Drug substance handling and bulk blending into finished product
- Metering or dosing mechanism compatibility support (platform dependent)
- Device integration and combination-product QA
Where device supply matters
The inhaler device can be a gating item for procurement timing and change control. Many programs run under a combination-product quality agreement with the device owner, which constrains substitute vendor options.
What is the supplier landscape by product type (DPI vs MDI) for fluticasone/salmeterol?
Fluticasone/salmeterol is sold in multiple inhaler formats. Supplier mapping differs by platform because the manufacturing line and device sourcing differ.
Dry powder inhaler (DPI) supply characteristics
- formulation is sensitive to micronization and blend homogeneity
- suppliers focus on inhalation powder manufacturing and device metering performance
Metered dose inhaler (MDI) supply characteristics
- formulation depends on propellant compatibility (if MDI)
- suppliers focus on can filling, valve integrity, and dose uniformity
Which upstream suppliers provide critical intermediates for fluticasone and salmeterol?
Inhalation APIs use multi-step chemistry, and procurement frequently sources intermediates through certified chemical suppliers. These intermediates are often controlled by supplier capability, patent-restricted synthetic routes, and know-how transfer agreements.
Typical intermediate procurement categories
- fluticasone propionate core intermediate synthesis (steroid chemistry intermediates)
- salmeterol xinafoate key aromatic/side-chain intermediates and salt-formation materials
- common reagents with regulated impurity constraints (e.g., halogenated solvents and catalyst residues)
Practical procurement constraint
Even when multiple chemical suppliers exist, qualification is narrower because inhalation programs demand tight impurity control aligned to finished drug specifications.
What packaging and inhaler device suppliers support fluticasone/salmeterol combinations?
Finished-dose supply for inhaled corticosteroid/LABA combinations depends on packaging and sometimes device supply:
- blistering or tray packing for DP
- canister/actuator assembly for MDI
- carton and leaflet supply
- device QA and combination product batch documentation
Procurement gating items
- component traceability and serialization support
- compatibility with primary container system
- stability-supporting materials
Which countries have the deepest fluticasone/salmeterol supply capacity?
For API and drug product manufacturing, capacity is concentrated in jurisdictions with established GMP regimes and inhalation experience.
Common capacity hubs
- India and China for API and intermediates (with varying DMF readiness)
- EU for some fine-chemical and inhalation form factor capabilities
- US and EU for finished dose manufacturing and device-integrated programs
How does supplier selection affect patent, regulatory, and litigation risk for fluticasone/salmeterol?
Supplier selection intersects with patent strategy because:
- sourcing routes can implicate process patents and know-how
- DMF or ASMF content affects regulatory submissions
- impurities and analytical comparability influence regulatory defensibility
Risk points for procurement and regulatory
- changing API supplier can require bridging stability and comparability work
- different intermediate suppliers can shift impurity signatures
- inhaler performance and dose uniformity requirements can be sensitive to drug substance variation
What is the Orange Book or FDA data linkage for fluticasone/salmeterol “supplier” visibility?
For branded and generic programs, supplier identities are most reliably extracted from:
- FDA device and drug product labeling references
- DMF/ASMF linkages in FDA submissions
- Orange Book listing history for product-specific exclusivities and patents
How to use FDA data in supplier due diligence
- map each marketed NDC to specific listed patents and exclusivity periods
- use the product’s regulatory history to determine whether the drug substance is sourced under a particular DMF/ASMF
- tie DMF holders to API and intermediates provenance
Supplier landscape summary table (what to map and how procurement teams categorize it)
| Supply layer |
What to procure |
Supplier category |
Procurement evidence to request |
| API |
Fluticasone propionate |
API manufacturer |
GMP CoA, DMF/ASMF linkage, impurity spec, traceability |
| API |
Salmeterol xinafoate |
API manufacturer |
Salt form controls, genotox/impurity profile, residual solvent limits |
| Drug substance |
API blended intermediate to drug substance |
Drug substance contractor |
Batch records, comparability, stability data |
| Drug product |
Filled inhalation product |
CMO/DP manufacturer |
Platform-specific batch records, dose uniformity data |
| Device |
Actuator, metering chamber, valves (platform dependent) |
Device supplier |
Component CoC, compatibility studies, change control history |
| Packaging |
Canisters/blisters, cartons, inserts |
Packager |
Primary packaging spec, stability-supporting materials |
Key Takeaways
- The fluticasone propionate + salmeterol xinafoate supply chain is layered: API makers, drug-substance/DP CMOs, and device/packaging suppliers.
- Vendor qualification is constrained by inhalation-specific performance attributes, impurity control, and device-drug compatibility rather than by the number of potential chemical suppliers.
- Supplier selection has regulatory and IP implications because DMF/ASMF linkages and impurity profiles affect comparability and submission defensibility.
FAQs
- How do I identify fluticasone propionate and salmeterol xinafoate API DMF holders for a specific NDC?
- What documentation is required to qualify a new fluticasone propionate API supplier for an inhalation product?
- Which impurity controls are most critical for salmeterol xinafoate salt form consistency?
- How does inhaler platform choice (DPI vs MDI) change the supplier qualification and CMO lineup?
- How do packaging and device component changes trigger combination-product regulatory work for fluticasone/salmeterol?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. (n.d.). Drug Master Files (DMF). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-master-files-dmf
